Results 41 to 50 of about 29,070 (238)
Arthritis Care &Research, EarlyView.Objective This study aimed to investigate hand function trajectories over five years in primary hand osteoarthritis (OA). Additionally, determinants of baseline and longitudinal hand function were assessed. Methods A total of 538 patients with both baseline and five‐year study visits were analyzed.
Annemiek V. E. M. Olde Meule +4 more
wiley +1 more source
Unusual presentation of adult Gaucher′s disease: A long and difficult road to diagnosis
Indian Journal of Endocrinology and Metabolism, 2011 Gaucher′s disease is the most frequent sphingolipid storage disease. We present a case of type 1 non-neuropathic type of adult Gaucher′s disease patient with atypical presentation.
Vishakha V Jain, Samir Yelwatkar
doaj +1 more source
No Difference in Health Related Quality of Life Between Therapeutic Options for Type 1 Gaucher Disease [PDF]
, 2016 Type 1 Gaucher disease (GD) is the most common lysosomal storage disorder. Previously, treatment for GD was limited to intravenous enzyme replacement therapy (ERT).
Wagner, Victoria
core +1 more source
Advanced Healthcare Materials, EarlyView.Surface polarization of PVDF films combined with mechanical stimulation generates piezoelectric electrical cues that modulate cardiomyoblast behaviour. Non‐poled and poled PVDF substrates provide distinct electroactive microenvironments influencing cell adhesion, proliferation, and differentiation.
Rafaela M Meira +3 more
wiley +1 more source
Unexpected macrophage-independent dyserythropoiesis in Gaucher disease
Haematologica, 2016 Gaucher disease is a rare inherited disease caused by a deficiency in glucocerebrosidase leading to lipid accumulation in cells of mononuclear-macrophage lineage known as Gaucher cells.
Nelly Reihani +9 more
doaj +1 more source
Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease [PDF]
, 2017 Background Gaucher disease (GD) is caused by mutations in the GBA1 gene which encodes lysosomal β-glucocerebrosidase (GCase). In GD, partial or complete loss of GCase activity causes the accumulation of the glycolipids glucosylceramide ...
Cotán, David +9 more
core +3 more sources
Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine
BMEMat, EarlyView.Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo +9 more
wiley +1 more source
Osteoarticular pathology in Gaucher disease, complicated by tuberculosis (clinical observations)
Гений oртопедии, 2022 Introduction Gaucher disease belongs to the group of hereditary lysosomal orphan cumulative diseases caused by deficiency of the β-glucocerebrosidase enzyme. It features polysystemic affection, including bone tissue. The osteoarticular system in Gaucher
Lyudmila A. Semenova +2 more
doaj +1 more source
Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal grafting [PDF]
, 2017 The blood–brain barrier (BBB) plays a fundamental role in protecting and maintaining the homeostasis of the brain. For this reason, drug delivery to the brain is much more difficult than that to other compartments of the body. In order to bypass or cross
Carafa, Maria +5 more
core +1 more source
Gaucher Disease and the Synucleinopathies [PDF]
BioMed Research International, 2006 Several recent observations suggest a connection between Gaucher disease, the inherited deficiency of glucocerebrosidase, and the synucleinopathies. Rare patients have been observed who develop both Gaucher disease and parkinsonism. Autopsy studies on these subjects reveal synuclein‐positive Lewy bodies and inclusions.
Hruska, Kathleen S. +2 more
openaire +2 more sources